about
Neonatal clinical pharmacologyClinical pharmacology of midazolam in neonates and children: effect of disease-a reviewUnderstanding and applying pharmacometric modelling and simulation in clinical practice and researchA re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data.Changes in individual drug-independent system parameters during virtual paediatric pharmacokinetic trials: introducing time-varying physiology into a paediatric PBPK modelPrediction of Human Glomerular Filtration Rate from Preterm Neonates to Adults: Evaluation of Predictive Performance of Several Empirical ModelsCharacterizing the Developmental Trajectory of Sirolimus Clearance in Neonates and InfantsProfound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children.Neonatal pharmacology: extensive interindividual variability despite limited size.Physiologically based pharmacokinetic (PBPK) modeling in children.Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations.The interplay between drugs and the kidney in premature neonates.Pharmacokinetic-pharmacodynamic modelling in anaesthesia.Methods for pharmacokinetic analysis in young children.Prediction of drug clearance in children: an evaluation of the predictive performance of several models.Prediction of drug clearance in children: a review of different methodologies.A novel maturation function for clearance of the cytochrome P450 3A substrate midazolam from preterm neonates to adults.Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure.Pharmacokinetics of sufentanil during long-term infusion in critically ill pediatric patients.Developmental pharmacology; filling one knowledge gap in pediatric anesthesiology.Extrapolation of praziquantel pharmacokinetics to a pediatric population: a cautionary tale
P2860
Q26992019-562012D5-3F3B-4305-B23E-3387D2C49CC8Q27006333-259452A4-5BB8-4EC9-8273-3146D9174444Q28468334-D15151E5-8EDC-4AAC-BF28-1EC03023BB23Q30786488-7451E6C1-619D-4CB1-B559-AA8615BA85B1Q33574126-8CE37B70-83BC-4055-A8FC-04A31266FE68Q36653892-9505FABC-5B9C-4AFF-A558-3F6CF51C300EQ37208505-9A746C28-62D2-47EA-92D6-226279862936Q37872786-882EA18A-AA2D-4C51-9E60-162808ECE403Q38000252-B9E156DF-6774-492E-ABBE-CAA6829505B9Q38016332-926DFE83-5507-4703-B147-601B799AC3BBQ38086777-BF614193-D6B9-4751-898B-9F136096A1CDQ38161817-8C571F3A-1F3C-4CEA-970A-D1FA48884B2FQ38164107-A6596AB2-F4F9-491E-A1A4-A6B1CED1C13AQ38187157-3E62B430-1DA0-4DFD-8EF0-CF0814B91A7FQ38256006-92A1A552-0C2F-4E0F-A41E-8D6966EFA9DEQ38367747-D5BF5FF0-8953-4292-9FBD-41B8D00EE209Q45247905-2BCF07DC-A3D2-4178-946F-A4428C891C23Q47600971-E2809964-D9F9-4796-BBB2-36E0578F9AD7Q47684945-F434EF9C-ACB2-4FEE-9688-C105A13B33C4Q48286613-79B7DA51-8174-4B3F-8B90-0824D1332F41Q58738240-68CE54C6-251B-4898-9C4A-3BB26B3DD86D
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
A maturation model for midazolam clearance.
@en
A maturation model for midazolam clearance.
@nl
type
label
A maturation model for midazolam clearance.
@en
A maturation model for midazolam clearance.
@nl
prefLabel
A maturation model for midazolam clearance.
@en
A maturation model for midazolam clearance.
@nl
P2860
P1476
A maturation model for midazolam clearance.
@en
P2093
Brian J Anderson
Peter Larsson
P2860
P304
P356
10.1111/J.1460-9592.2010.03364.X
P577
2011-03-01T00:00:00Z